Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070303 · ClinicalTrials.gov registry record · Phase 3
Remission in Subjects With Crohn's Disease, Open Label Extension
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT01070303 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 177 participants.
The verdict
NCT01070303, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.
Interventions
- BIOLOGICAL Adalimumab 40 mg eow or ew
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2002-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01070303
The ClinicalTrials.gov registry entry for NCT01070303 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adalimumab 40 mg eow or ew is the first listed.
NCT01070303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01070303 about?
NCT01070303 is a clinical study titled "Remission in Subjects With Crohn's Disease, Open Label Extension". The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.
What is the current status of trial NCT01070303?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2002-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT01070303?
The interventions under investigation include: Adalimumab 40 mg eow or ew (BIOLOGICAL).
Who is sponsoring clinical trial NCT01070303?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.